Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 3/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 5/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909196 | 1.00 | VNN1 (0.52) | VNN1ROCK2GRM5GABRA5SPHK2 | |
| SCHEMBL17600726 | 0.96 | GRM5 (0.55) | VNN1ROCK2GRM5GABRA5SPHK2 | |
| SCHEMBL17600723 | 0.96 | GRM5 (0.55) | VNN1ROCK2GRM5GABRA5SPHK2 | |
| SCHEMBL5908973 | 0.86 | HRH3 (0.56) | GRM5 | |
| SCHEMBL5909290 | 0.86 | POLB (0.50) | GRM5CNR1CNR2LMNAPOLB | |
| SCHEMBL5909114 | 0.86 | GRM5 (0.66) | GRM5CNR1CNR2LMNAALDH1A1 | |
| SCHEMBL5909188 | 0.82 | GAA (0.63) | VNN1GRM5GABRA5CNR1CNR2 | |
| SCHEMBL5909293 | 0.82 | GAA (0.63) | VNN1GRM5GABRA5CNR1CNR2 | |
| SCHEMBL5909226 | 0.82 | GAA (0.63) | VNN1GRM5GABRA5CNR1CNR2 | |
| SCHEMBL5909206 | 0.82 | CNR1 (0.50) | ROCK2GRM5SPHK2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | VNN1 2897/4885ROCK2 1417/4885GRM5 3409/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | VNN1 2577/4885ROCK2 1347/4885GRM5 2486/4885 |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | NAMPT, NNT, SIRT1 | VNN1 141/4885ROCK2 2872/4885GRM5 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.